Abstract
AbstractDendritic cell (DC) vaccines play an important role in anti‐tumor immunotherapy. Tumor‐associated cells or cytokines in the tumor microenvironment (TME) can inhibit the antigen‐presenting function of DC. Immunogenic cell death (ICD) can enhance the uptake and presentation of tumor antigens by DC. This study investigates the maturation mechanism of DC induced by low‐temperature plasma (LTP), as well as the therapeutic and protective effects of LTP‐induced DC vaccine in a tumor model. DC2.4 that is co‐cultured with LTP‐treated B16F10 (LTP‐B16) or with these supernatants exhibited decreased phagocytic activity, increased production of cytokines (IL‐12, IL‐6, TNF‐α, and IL‐1β), and increased expression of cell surface activation markers (CD80, CD86, and MHC II). The expression of CD80+/CD86+ is decreased after pre‐treatment with TLR4 and NF‐κB (p65) inhibitors, respectively. In vivo, trials indicated that the LTP‐induced DC vaccine‐induced anti‐tumor immunity and, when combined with cisplatin, synergistically reduced tumor growth.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
